BEIGENE (06160) shares are soaring 7.60% in early trading on Wednesday, reaching HK$209.40, as investors react to the company's impressive third-quarter financial results and positive analyst forecasts.

The innovative biopharmaceutical company reported a significant milestone in its Q3 earnings, with revenue surpassing RMB 10 billion for the first time. The company's revenue reached RMB 10.077 billion, marking a year-on-year increase of 41.1%. This strong performance was primarily driven by robust sales growth of its key products, including the BTK inhibitor Brukinsa (zanubrutinib) and PD-1 inhibitor tislelizumab, as well as increased revenue from Amgen-authorized products.

Following the positive results, several analysts have upgraded their forecasts for BEIGENE. Bank of Communications International raised its net profit forecast for the company by 3% to 52%, citing more optimistic expectations for operating expense ratios. Meanwhile, Haitong International revised its revenue projections for 2025–2027, now expecting revenues of $5.3 billion, $6.4 billion, and $7.1 billion respectively, reflecting a compound annual growth rate of 23%. The upgrades were largely based on zanubrutinib's sales exceeding expectations in both the US and European markets.